CITIUS ONCOLOGY, INC. financial data

Symbol
CTOR on Nasdaq
Location
Cranford, NJ
Fiscal year end
30 September
Latest financial report
10-Q - Q4 2025 - 13 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 51% % 49%
Quick Ratio 39% %
Debt-to-equity 130% %
Return On Equity -55% % 26%
Return On Assets -24% % 29%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 84,797,846 shares 19%
Common Stock, Shares, Outstanding 84,797,846 shares 19%
Entity Public Float $5,097,850 USD -100%
Common Stock, Value, Issued $8,480 USD 19%
Weighted Average Number of Shares Outstanding, Basic 87,462,385 shares 22%
Weighted Average Number of Shares Outstanding, Diluted 87,462,385 shares 22%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $3,944,111 USD
Cost of Revenue $789,208 USD
Research and Development Expense $6,172,178 USD 22%
General and Administrative Expense $8,321,357 USD -16%
Operating Income (Loss) $5,252,276 USD 18%
Nonoperating Income (Expense) $17,553 USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $22,579,273 USD -0.87%
Income Tax Expense (Benefit) $1,056,960 USD 52%
Net Income (Loss) Attributable to Parent $23,636,233 USD -2.4%
Earnings Per Share, Basic -0.31 USD/shares 6.1%
Earnings Per Share, Diluted -0.31 USD/shares 6.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $112 USD
Accounts Receivable, after Allowance for Credit Loss, Current $4,049,111 USD
Inventory, Net $22,639,342 USD 57%
Assets, Current $37,146,844 USD 117%
Assets $109,973,406 USD 22%
Accounts Payable, Current $10,446,900 USD 78%
Accrued Liabilities, Current $4,518,916 USD -27%
Liabilities, Current $44,710,394 USD 3%
Deferred Income Tax Liabilities, Net $3,049,200 USD 53%
Liabilities $51,559,705 USD 4.8%
Retained Earnings (Accumulated Deficit) $69,574,025 USD -51%
Stockholders' Equity Attributable to Parent $58,413,701 USD 41%
Liabilities and Equity $109,973,406 USD 22%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $7,354,946 USD
Net Cash Provided by (Used in) Financing Activities $15,125,489 USD
Net Cash Provided by (Used in) Investing Activities $4,400,000 USD
Common Stock, Shares Authorized 400,000,000 shares 300%
Common Stock, Shares, Issued 84,797,846 shares 19%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $584 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $112 USD
Interest Paid, Excluding Capitalized Interest, Operating Activities $14,460 USD
Deferred Tax Assets, Valuation Allowance $19,418,000 USD 65%
Deferred Income Tax Expense (Benefit) $264,240 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards $12,720,000 USD 69%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $127,979,246 USD 47%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $8,116,678 USD 8.2%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%